{
    "hands_on_practices": [
        {
            "introduction": "The foundation of managing pediatric HIV is accurate and timely diagnosis. However, no diagnostic test is perfect, and its reliability in a real-world setting depends not only on its intrinsic accuracy but also on the prevalence of the disease in the population being tested. This exercise  demonstrates how to apply Bayes' theorem to calculate the positive predictive value of a virologic test, a critical skill for interpreting results correctly and providing clear guidance to caregivers.",
            "id": "5185310",
            "problem": "In a regional Early Infant Diagnosis (EID) program for Human Immunodeficiency Virus (HIV) among HIV-exposed infants at six weeks of age, the prevalence of true HIV infection among those infants who present for testing is estimated to be five percent ($0.05$). The standard virologic assay used is an HIV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR), which has been validated in this population with sensitivity equal to ninety-five percent ($0.95$) and specificity equal to ninety-nine percent ($0.99$). Using Bayes’ theorem together with the definitions of sensitivity, specificity, and prevalence as probabilities, derive from first principles the posterior probability that an infant with a positive PCR truly has HIV infection, and then calculate this quantity. Express your final answer as a decimal number rounded to four significant figures.",
            "solution": "The problem is assessed to be valid as it is scientifically grounded, well-posed, objective, and contains all necessary information for a unique solution. The principles involved—prevalence, sensitivity, specificity, and Bayes' theorem—are fundamental concepts in biostatistics and epidemiology.\n\nLet us define the following events:\n- $H$: The event that an infant truly has HIV infection.\n- $H^c$: The event that an infant does not have HIV infection.\n- $T^+$: The event that the HIV PCR test result is positive.\n- $T^-$: The event that the HIV PCR test result is negative.\n\nFrom the problem statement, we are given the following probabilities:\n1.  The prevalence of true HIV infection is $5\\%$. This is the prior probability of an infant having HIV, which we denote as $P(H)$.\n    $$P(H) = 0.05$$\n2.  The sensitivity of the test is $95\\%$. Sensitivity is the probability that the test is positive, given that the infant has the infection.\n    $$P(T^+ | H) = 0.95$$\n3.  The specificity of the test is $99\\%$. Specificity is the probability that the test is negative, given that the infant does not have the infection.\n    $$P(T^- | H^c) = 0.99$$\n\nFrom these given values, we can derive other necessary probabilities. The probability that an infant does not have HIV is the complement of the prevalence:\n$$P(H^c) = 1 - P(H) = 1 - 0.05 = 0.95$$\nThe probability of a positive test result in an infant who does not have HIV is the complement of the specificity. This is also known as the false positive rate.\n$$P(T^+ | H^c) = 1 - P(T^- | H^c) = 1 - 0.99 = 0.01$$\n\nThe goal is to find the posterior probability that an infant with a positive PCR test truly has HIV infection. This is the conditional probability $P(H | T^+)$, also known as the Positive Predictive Value (PPV).\n\nAccording to Bayes' theorem, this probability is given by:\n$$P(H | T^+) = \\frac{P(T^+ | H) P(H)}{P(T^+)}$$\n\nThe denominator, $P(T^+)$, represents the total probability of obtaining a positive test result. We can calculate this using the law of total probability. A positive test can occur in two mutually exclusive scenarios: a true positive (the infant has HIV and tests positive) or a false positive (the infant does not have HIV but tests positive).\nMathematically, this is expressed as:\n$$P(T^+) = P(T^+ \\cap H) + P(T^+ \\cap H^c)$$\nUsing the definition of conditional probability, $P(A \\cap B) = P(A|B)P(B)$, we can write:\n$$P(T^+) = P(T^+ | H) P(H) + P(T^+ | H^c) P(H^c)$$\n\nSubstituting this expression for $P(T^+)$ back into the Bayes' theorem formula, we get the complete expression for the posterior probability we seek:\n$$P(H | T^+) = \\frac{P(T^+ | H) P(H)}{P(T^+ | H) P(H) + P(T^+ | H^c) P(H^c)}$$\n\nNow, we substitute the numerical values into this formula:\n$$P(H) = 0.05$$\n$$P(H^c) = 0.95$$\n$$P(T^+ | H) = 0.95$$\n$$P(T^+ | H^c) = 0.01$$\n\nThe calculation proceeds as follows:\n$$P(H | T^+) = \\frac{(0.95)(0.05)}{(0.95)(0.05) + (0.01)(0.95)}$$\n\nFirst, calculate the numerator, which represents the probability of a true positive result in the population:\n$$\\text{Numerator} = 0.95 \\times 0.05 = 0.0475$$\n\nNext, calculate the terms in the denominator. The first term is the same as the numerator. The second term represents the probability of a false positive result in the population:\n$$\\text{Second term of denominator} = 0.01 \\times 0.95 = 0.0095$$\n\nThe denominator is the sum of these two probabilities, representing the total probability of a positive test:\n$$\\text{Denominator} = 0.0475 + 0.0095 = 0.0570$$\n\nFinally, we compute the ratio:\n$$P(H | T^+) = \\frac{0.0475}{0.0570}$$\n$$P(H | T^+) = 0.833333...$$\n\nThe problem requires the answer to be expressed as a decimal number rounded to four significant figures.\n$$P(H | T^+) \\approx 0.8333$$\nThis result signifies that even with a highly specific test, in a population with relatively low prevalence, a positive result indicates an $83.33\\%$ probability of the infant actually having the disease.",
            "answer": "$$\\boxed{0.8333}$$"
        },
        {
            "introduction": "Once an infant is identified as HIV-exposed, the immediate priority is to prevent vertical transmission through antiretroviral prophylaxis. Correctly dosing these medications is a fundamental and non-negotiable skill in pediatric care, as dosages must be precisely tailored to the infant's weight to ensure both safety and efficacy. This practice problem  provides essential hands-on experience in performing a basic weight-based dose calculation, a cornerstone of pediatric pharmacology.",
            "id": "5185376",
            "problem": "A term neonate born to a mother with Human Immunodeficiency Virus (HIV) exposure is prescribed zidovudine prophylaxis according to standard neonatal dosing. The dosing regimen is $4\\,\\mathrm{mg}/\\mathrm{kg}$ per administration, given every $12$ hours. The infant’s weight at the time of prescription is $4.5\\,\\mathrm{kg}$. Using only the fundamental relationship that a mass-normalized dose scales linearly with body mass, and that total daily dose equals the dose per administration multiplied by the number of administrations per day, derive the total daily zidovudine amount in milligrams for this infant. You may compute the per-administration dose as an intermediate step, but report only the total daily dose as your final numeric answer. Express the final result in $\\mathrm{mg}$. Round your final answer to four significant figures.",
            "solution": "The problem is validated as self-contained, scientifically grounded, and well-posed. All necessary data are provided, and the principles cited are fundamental to pharmacology and arithmetic.\n\nThe objective is to derive the total daily dose of zidovudine for a neonate based on the provided parameters. The derivation will proceed in two steps as suggested by the problem statement: first, calculating the dose per administration, and second, calculating the total daily dose.\n\nThe given parameters are:\n- Mass-normalized dose, $D_{\\text{norm}} = 4\\,\\mathrm{mg}/\\mathrm{kg}$ per administration.\n- Infant's body mass, $m = 4.5\\,\\mathrm{kg}$.\n- Administration interval, $T_{\\text{interval}} = 12\\,\\mathrm{h}$.\n\nFirst, we calculate the dose for a single administration, denoted as $D_{\\text{single}}$. The problem states that the dose scales linearly with body mass. Therefore, $D_{\\text{single}}$ is the product of the mass-normalized dose and the infant's body mass.\n$$D_{\\text{single}} = D_{\\text{norm}} \\times m$$\nSubstituting the given values:\n$$D_{\\text{single}} = (4\\,\\mathrm{mg}/\\mathrm{kg}) \\times (4.5\\,\\mathrm{kg})$$\nThe kilograms ($\\mathrm{kg}$) units cancel, yielding a result in milligrams ($\\mathrm{mg}$).\n$$D_{\\text{single}} = 18\\,\\mathrm{mg}$$\n\nNext, we determine the number of administrations per day, denoted as $N_{\\text{admin}}$. The total duration of a day is $T_{\\text{day}} = 24\\,\\mathrm{h}$. The drug is administered every $T_{\\text{interval}} = 12\\,\\mathrm{h}$. The number of administrations per day is the ratio of the total time in a day to the administration interval.\n$$N_{\\text{admin}} = \\frac{T_{\\text{day}}}{T_{\\text{interval}}}$$\nSubstituting the time values:\n$$N_{\\text{admin}} = \\frac{24\\,\\mathrm{h}}{12\\,\\mathrm{h}} = 2$$\nSo, there are $2$ administrations per day.\n\nFinally, we calculate the total daily dose, $D_{\\text{total}}$, which is the product of the dose per single administration and the number of administrations per day, as stated in the problem.\n$$D_{\\text{total}} = D_{\\text{single}} \\times N_{\\text{admin}}$$\nSubstituting the calculated intermediate values:\n$$D_{\\text{total}} = 18\\,\\mathrm{mg} \\times 2$$\n$$D_{\\text{total}} = 36\\,\\mathrm{mg}$$\n\nThe problem requires the final answer to be rounded to four significant figures. The calculated value is an exact integer, $36$. To express this with four significant figures, we write it as $36.00$.",
            "answer": "$$\\boxed{36.00}$$"
        },
        {
            "introduction": "Long-term management of HIV requires vigilance for treatment failure, which is often caused by the virus evolving resistance to medication. When this occurs, clinicians must turn to genotypic resistance testing to guide the selection of a new, effective regimen. This advanced exercise  simulates the complex clinical reasoning required to interpret a genetic report, applying knowledge of how specific viral mutations interact to predict the remaining effectiveness of a drug and inform critical treatment decisions.",
            "id": "5185360",
            "problem": "A child with Human Immunodeficiency Virus (HIV) infection, age $9$ years and weight $32$ kilograms, presents with virologic failure after $18$ months on a nucleos(t)ide reverse transcriptase inhibitor (NRTI)-based regimen. A plasma genotypic resistance test of HIV reverse transcriptase (RT) reveals the following substitutions: K65R, M41L, L210W, and T215Y. No other major NRTI or non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations are detected. You are asked to predict the residual activity of tenofovir against this virus to guide selection between Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF) as part of a new regimen.\n\nUse the following foundational definitions and well-tested observations to reason from mechanism to phenotype:\n\n- HIV RT catalyzes viral complementary DNA synthesis. NRTIs act as competitive substrates that, once incorporated as analogs, terminate the nascent DNA chain. The phenotypic susceptibility to a drug can be summarized by the half-maximal inhibitory concentration, $IC_{50}$. A resistance mutation increases the $IC_{50}$ relative to wild-type. The fold-change is defined as $F = IC_{50,\\ \\text{mutant}} / IC_{50,\\ \\text{wild-type}}$. As a first-order approximation, residual antiviral activity is inversely related to $F$, such that the fractional residual activity is approximately $1/F$.\n- The K65R substitution in RT reduces incorporation of tenofovir diphosphate and typically increases the tenofovir $IC_{50}$ by about $2.5$-fold in vitro for both TDF- and TAF-derived intracellular tenofovir diphosphate.\n- Thymidine Analog Mutations (TAMs) selected by zidovudine or stavudine come in recognizable patterns. The TAM-$1$ pattern (M41L, L210W, T215Y) increases tenofovir $IC_{50}$ via cross-resistance, typically by about $1.8$-fold when at least two of these are present.\n- When K65R co-occurs with TAMs, antagonistic interaction has been observed: the net effect on tenofovir $IC_{50}$ is less than the simple product of individual fold-changes. A conservative, empirically grounded way to capture this is to scale the multiplicative expectation by a factor $a$ with $0  a  1$. For this genotype combination, assume $a \\approx 0.70$.\n- Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) deliver the same active moiety, tenofovir diphosphate, intracellularly. TAF achieves higher intracellular levels at lower plasma exposures than TDF, but resistance substitutions that impair the interaction of tenofovir diphosphate with RT (for example, K65R and TAMs) affect both TDF- and TAF-derived tenofovir similarly, with any difference being quantitative rather than categorical.\n\nAssume wild-type $IC_{50}$ is normalized to $1.0$ arbitrary unit. Based on the above, choose the single best interpretation of the residual activity of tenofovir against this child’s virus and the clinical implication for selecting TDF versus TAF as part of the new regimen.\n\nA. The combined fold-change is approximately $3.2$, implying partial residual activity (about $30\\%$ of wild-type). TAF may retain slightly more functional activity than TDF owing to higher intracellular tenofovir diphosphate, but both should be used only to contribute activity within a regimen anchored by a high-barrier agent.\n\nB. The combined fold-change is approximately $4.5$, implying no meaningful residual activity; both TDF and TAF should be avoided entirely.\n\nC. The combined fold-change is approximately $2.5$, implying near-wild-type activity; TDF could function as the principal suppressive agent without the need for a high-barrier anchor.\n\nD. The combined fold-change is less than $1.0$ due to antagonism, implying hypersusceptibility; TDF activity is enhanced and superior to TAF in this setting.",
            "solution": "## Problem Validation\n\n### Step 1: Extract Givens\n\n- Patient: Child, age $9$ years, weight $32$ kilograms.\n- Clinical History: Diagnosed with Human Immunodeficiency Virus (HIV), experiencing virologic failure after $18$ months on a nucleos(t)ide reverse transcriptase inhibitor (NRTI)-based regimen.\n- Genotypic Data: HIV reverse transcriptase (RT) substitutions are K65R, M41L, L210W, and T215Y. No other major NRTI or non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations are present.\n- Objective: Predict the residual activity of tenofovir against this viral strain to inform the choice between Tenofovir Disoproxil Fumarate (TDF) and Tenofovir Alafenamide (TAF).\n- Definitions:\n    - Phenotypic susceptibility is measured by the half-maximal inhibitory concentration, $IC_{50}$.\n    - Fold-change is $F = IC_{50,\\ \\text{mutant}} / IC_{50,\\ \\text{wild-type}}$.\n    - Fractional residual activity is approximated as $1/F$.\n    - Wild-type $IC_{50}$ is normalized to $1.0$ arbitrary unit.\n- Observations on Resistance:\n    1. The K65R substitution increases the tenofovir $IC_{50}$ by approximately $2.5$-fold.\n    2. The Thymidine Analog Mutation (TAM) pattern TAM-$1$ (M41L, L210W, T215Y) increases the tenofovir $IC_{50}$ by approximately $1.8$-fold when at least two of these mutations are present. The patient's virus has all three.\n    3. When K65R and TAMs co-occur, an antagonistic interaction reduces the net effect. The scaling factor for this antagonism is $a \\approx 0.70$, where $0  a  1$. The net effect is the multiplicative expectation scaled by $a$.\n- Pharmacology:\n    - TAF and TDF deliver the same active moiety, tenofovir diphosphate.\n    - Resistance substitutions affect both TDF- and TAF-derived tenofovir similarly.\n    - TAF achieves higher intracellular tenofovir diphosphate levels than TDF.\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem statement is evaluated against the validation criteria:\n- **Scientifically Grounded:** The problem is firmly based on established principles of HIV virology and pharmacology. The mutations (K65R, TAMs), drugs (TDF, TAF), mechanism of action of NRTIs, concepts of $IC_{50}$, fold-change, and mutational antagonism are all standard and well-documented in the field of HIV medicine. The quantitative values provided for fold-changes and the antagonism factor are consistent with data from genotypic-phenotypic correlation studies.\n- **Well-Posed:** The problem is well-posed. It provides a clear set of initial conditions (the genotype), a quantitative model to process these conditions (the rules for calculating fold-change), and a specific question to answer (predict residual activity and choose between TDF/TAF). All necessary information is provided to derive a unique solution based on the given model.\n- **Objective:** The language is clinical, technical, and precise, free of subjective or ambiguous terminology.\n- **Flaw Checklist:**\n    - No scientific or factual unsoundness is present.\n    - The problem is formalizable and directly relevant to the topic.\n    - The setup is complete and internally consistent.\n    - The scenario is realistic and clinically plausible.\n    - The problem structure allows for a unique and stable solution based on the premises.\n    - The problem is not trivial; it requires the integration of multiple data points and an understanding of their interaction.\n    - The claims are based on verifiable scientific observations.\n\n### Step 3: Verdict and Action\n\nThe problem statement is **valid**. The solution process will proceed.\n\n## Solution Derivation\n\nThe problem requires us to calculate the total fold-change ($F_{net}$) in tenofovir $IC_{50}$ resulting from the given combination of mutations and then interpret the clinical implications.\n\n1.  **Identify the individual fold-change contributions:**\n    - The K65R mutation contributes a fold-change of $F_{K65R} \\approx 2.5$.\n    - The patient's virus has the M41L, L210W, and T215Y mutations. This is the TAM-$1$ pattern, and since all three mutations are present (which is more than the required \"at least two\"), this pattern contributes a fold-change of $F_{TAMs} \\approx 1.8$.\n\n2.  **Calculate the simple multiplicative fold-change:**\n    Without considering any interaction, the combined effect would be the product of the individual effects:\n    $$F_{mult} = F_{K65R} \\times F_{TAMs} \\approx 2.5 \\times 1.8 = 4.5$$\n\n3.  **Apply the antagonistic interaction factor:**\n    The problem states that when K65R and TAMs co-occur, there is an antagonistic interaction that scales the multiplicative expectation by a factor of $a \\approx 0.70$.\n    $$F_{net} = F_{mult} \\times a \\approx 4.5 \\times 0.70 = 3.15$$\n    So, the net fold-change in $IC_{50}$ is approximately $3.15$.\n\n4.  **Calculate the residual activity:**\n    The fractional residual activity is approximated as the reciprocal of the net fold-change:\n    $$\\text{Residual Activity} \\approx \\frac{1}{F_{net}} \\approx \\frac{1}{3.15} \\approx 0.317$$\n    This corresponds to approximately $31.7\\%$ of the activity against a wild-type virus.\n\n5.  **Interpret the clinical implications:**\n    - A fold-change of $3.15$ indicates a significant loss of susceptibility, but not complete resistance. This level is typically categorized as intermediate or partial resistance. Tenofovir is expected to have some, but reduced, antiviral effect.\n    - Given this partial activity, tenofovir (in either form, TDF or TAF) should not be relied on as a primary suppressive agent. Instead, it can contribute to viral suppression as part of a combination regimen that includes other fully active agents, particularly one with a high barrier to resistance (e.g., dolutegravir, boosted darunavir) to prevent further resistance development.\n    - The problem states that TAF achieves higher intracellular concentrations of the active tenofovir diphosphate. In the face of partial resistance, these higher drug levels can help to overcome the reduced enzyme affinity, potentially providing a greater \"functional\" or effective antiviral activity in vivo compared to TDF. Therefore, TAF may be a preferable choice over TDF in this specific context.\n\n## Option-by-Option Analysis\n\n**A. The combined fold-change is approximately $3.2$, implying partial residual activity (about $30\\%$ of wild-type). TAF may retain slightly more functional activity than TDF owing to higher intracellular tenofovir diphosphate, but both should be used only to contribute activity within a regimen anchored by a high-barrier agent.**\n\n- The calculated fold-change is $F_{net} = 3.15$, which is well-approximated by $3.2$.\n- The calculated residual activity is $\\approx 31.7\\%$, which is well-approximated by $30\\%$.\n- The clinical interpretation aligns perfectly with our derivation: the resistance is partial, tenofovir can contribute activity but requires a strong regimen backbone (a \"high-barrier agent\"), and TAF is likely a better choice than TDF due to its pharmacological advantage.\n- **Verdict: Correct**\n\n**B. The combined fold-change is approximately $4.5$, implying no meaningful residual activity; both TDF and TAF should be avoided entirely.**\n\n- This option uses the simple multiplicative fold-change ($2.5 \\times 1.8 = 4.5$) but fails to account for the explicitly stated antagonistic interaction factor $a \\approx 0.70$. The calculation is therefore incorrect according to the problem's premises.\n- **Verdict: Incorrect**\n\n**C. The combined fold-change is approximately $2.5$, implying near-wild-type activity; TDF could function as the principal suppressive agent without the need for a high-barrier anchor.**\n\n- This option incorrectly considers only the fold-change from the K65R mutation ($2.5$) and ignores the contribution of the TAMs ($1.8$) and the antagonism ($0.70$). The calculation is incomplete. Furthermore, a fold-change of $2.5$ is not \"near-wild-type activity\"; it represents a clinically significant degree of resistance. The clinical advice is therefore also flawed.\n- **Verdict: Incorrect**\n\n**D. The combined fold-change is less than $1.0$ due to antagonism, implying hypersusceptibility; TDF activity is enhanced and superior to TAF in this setting.**\n\n- This option misinterprets the meaning of antagonism. Antagonism in this context means the combined resistance effect is *less than* the multiplicative product, not that it reverses the effect into hypersusceptibility ($F  1.0$). Our calculation shows $F_{net} = 3.15$, which is much greater than $1.0$. The conclusion of hypersusceptibility is false. The claim that TDF is superior to TAF contradicts the pharmacological principle that TAF's higher intracellular concentrations are an advantage against partially resistant virus.\n- **Verdict: Incorrect**",
            "answer": "$$\\boxed{A}$$"
        }
    ]
}